OTR3 - Matrix Therapy Company in Regenerative Medecine
We are driven by a conviction: the only scientific research that matters is the one which brings tangible benefits to society. OTR3 was founded by two well-known biologists: Pr. OTR3’s executive committee is constituted of members with rich and complementary experiences including academic and medical backgrounds in both pharmaceutical and cosmetic industries. We are a biotechnology company developing medical devices based on tissue regeneration. OTR3 is a biotechnology company with a strong focus on the development of matrix therapy. ISO 13485 certified, OTR3 internationally markets products as medical devices for humans and veterinary comfort products (Europe, South America, North America, the Middle East and Asia). OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars. As a French biotech company, we are developing products for tissue regeneration utilizing matrix therapy to improve the life of patients who suffer dermatological or neurological disorders.
This company is:
Verified
Extracellular Matrix Degradation - OTR3
Extracellular MatrixDegradation Tissue lesions will result in the degradation of the extracellular environment In a living tissue, cells are surrounded by an environment composed of a variety of constituents, called the Extracellular Matrix (ECM), that plays a key role in tissue homeostasis (i.e. the capacity of a living tissue to maintain its functional equilibrium). When […]
Verified
Tissue Regeneration with RGTA® - OTR3
Tissue regeneration with RGTA® RGTA® helps restore the original tissue, resulting in effective tissue regeneration RGTA® molecules provide a temporary substitute, replacing the degraded Heparan Sulfates (HS). RGTA® have been specifically designed to be more resistant to enzymatic degradation, while maintaining the natural functionality of HS to store and protect communication peptides. RGTA® molecules help to […]
Verified
Tissue Repair without RGTA® - OTR3
Tissue repair without RGTA® Dysfunctional tissue repair will generally lead to fibrosis or chronic wound Inflammatory and immune cells control “emergency” signals to repair the injury. These “emergency” repair signals are not tissue specific and the repair process is more focused on bridging wound openings rather than preserving tissue homeostasis. This “emergency” repair may leave […]
View all products
Keywords
Industries
Clinical Cases - OTR3
Clinical Cases for Cacipliq 20® Our chronic wound healing product has been used up to date by more than 200 000 patients. A selection of some clinical cases of patients treated with Cacipliq 20® are presented in this section, and more are available upon request. Please note that this document is destined to health professionals and […]
Where is OTR3 located?
The company OTR3 is located in Paris, Ile-de-France, France. It's worth noting that the company may has more corporate locations
How many employees does OTR3 approximately have?
As of the latest available information OTR3 has around 11-50 employees worldwide.
When was OTR3 founded?
OTR3 was founded in 2000
In which industries does OTR3 mainly work?
The company OTR3 has it's main focus in the industries of Biotechnology, Science and Engineering
Tissue Regeneration Therapeutics
Canada
1-10 Employees
2004
BioTissue
2003
Oblique Therapeutics
Sweden
1-10 Employees
2015
TheOTCLab
Netherlands
1-10 Employees
2016
Ourobionics
Netherlands
1-10 Employees
2020
ONA Therapeutics
Spain
11-50 Employees
2019
M2RLAB
Spain
1-10 Employees
2015
TEXERE Biotech
Belgium
11-50 Employees
2016
Topics which have been searched by others and may be interesting for you:
